DLC1 deficiency at diagnosis predicts poor prognosis in acute myeloid leukemia

Xueqian Li1,2†, Jiaqian Qi1,2,3†, Xiaofei Song1,2†, Xiaoyan Xu1,2, Tingting Pan1,2, Hong Wang1,2,3, Jingyi Yang1,2 and Yue Han1,2,3,4*©

Abstract

Acute myeloid leukemia (AML) is a complex, heterogeneous malignant hematologic disease. Although multiple prognostic-related genes were examined in previous studies, there are still many genes whose prognostic value remains unclear. In this study, a total of 1532 AML patients from three GEO databases were included, five genes with potential prognostic value (DLC1, NF1B, DENNDS5B, TANC2 and ELAVL4) were screened by weighted gene co-expression network analysis (WGCNA), least absolute shrinkage and selection operator (LASSO) and support vector machine recursive feature elimination (SVM-RFE). Based on this, we conducted survival analysis of the above five genes through the TCGA database and found that low level of DLC1 was detrimental to the long-term prognosis of AML patients. We also performed external validation in 48 AML patients from our medical center to analyze the impact of DLC1 level on prognosis. In conclusion, DLC1 may be a potential marker affecting the prognosis of AML, and its deficiency is associated with poor prognosis.

Keywords: Acute myeloid leukemia, Weighted gene co-expression network analysis, Differential gene expression analysis, DLC1, Machine learning

To the Editor,

Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy characterized by malignant proliferation and abnormal differentiation of myeloid blasts [1]. The prognosis of AML remains poor, with 5-year overall survival rate below 50% after diagnosis and 2-year survival rate of only 20%–30% in elderly patients [2, 3]. Currently, molecular and genetic advances have increased our understanding of the pathogenesis and progression of AML [4, 5], and further discovery of genes associated with prognosis can broaden therapeutic options for AML patients. This study aimed to identify novel prognostic genes for AML through a multi-perspective and multi-dimensional analysis of the GEO database and validation using the TCGA database and our center’s data.

As shown in the workflow (Fig. 1A), three datasets with survival outcomes were downloaded from the GEO databases, and 1532 patients were included for follow-up analysis (562 in GSE37642, 534 in GSE76009, and 436 in GSE16432). A total of 151 AML patients with RNA-seq data were enrolled from the TCGA database. Five hundred and five differentially expressed genes (DEGs) in the GEO datasets were screened using $|\log FC| \geq 1.0$ and adj. p-value < 0.05 as cut-off criteria. The heat map shows 50 genes with the highest variability (Fig. 1B), and the volcano map displays the up-and down-regulated genes among these differential genes (Fig. 1C). Towards
a comprehensive understanding of the potential function of these genes in the co-expression modules, the Gene Ontology (GO) enrichment analysis was performed and divided genes into three categories: biological processes (BP), cellular components (CC), and molecular functions (MF) (Fig. 1D). In BP, genes were enriched in GTPase activity and Golgi vesicle transport. Many genes are involved in the cell leading edge, transport vesicle, and transcription regulator complex in the CC category. In addition, protein serine/threonine kinase activity and Ras GTPase binding were mainly involved in MF. Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis showed that genes were enriched in choline metabolism in cancer (Fig. 1E).

Two thousand three hundred and forty-one co-expressed genes were extracted from these significant modules based on weighted gene co-expression network analysis (WGCNA) [6] (Fig. 2A). We compared the status of patients (alive or dead) in different sets of genes and found the most significant degree of variability in the gray gene set (Fig. 2B). We also analyzed the correlation of gene significance and module membership in patients with different survival statuses in both gray and blue modules (Additional file 1: Fig. S1). We intersected the eligible differential genes with the genes in the WGCNA gray gene set. Finally, 22 overlapping genes were obtained at the junction of the DEGs list and the two co-expression modules (Additional file 2: Fig. S2). Then, least absolute shrinkage and selection operator (LASSO) regression screening was performed based on the partial likelihood deviation method to obtain the corresponding coefficients with an optimal log λ of −4.35, of which 21 genes were suitable for constructing the model [7] (Additional file 3: Fig. S3A, B).

Meanwhile, five genes were identified by the support vector machine algorithm with the optimal five CV accuracy [8] (Additional file 3: Fig. S3C). Moreover, the five shared biomarkers of AML were defined by overlapping the biomarkers derived from the two algorithms (Additional file 3: Fig. S3D). These five specific genes (DLC1, NF1B, DENND5B, TANC2, ELAVL4) are associated with the prognosis of AML. We performed a survival analysis of the above five genes using GEO data (Fig. 2C–G) and found that AML patients with low DLC1 level had a poorer overall prognosis (Fig. 2C, $p=0.003$). Median was regarded as cut-off value. Survival data from TCGA data showed similar results (Fig. 2H, $p=0.048$). Meanwhile, we analyzed the expression of relevant genes in
Fig. 2 Co-expression network based on WGCNA to identify modules associated with AML survival status and survival analysis of candidate hub genes. 

A Clustering dendrogram of co-expression modules screened based on AML-related samples from the GEO database. 

B Module-trait relationships between gene modules and survival status of AML patients. 

C–G Kaplan–Meier survival analysis based on DLC1 (C), NF1B (D), DENND5B (E), TANC2 (F), and ELAVL4 (G) expression in AML patients from the GEO database. 

H Kaplan–Meier survival analysis based on DLC1 expression in AML patients from TCGA database. *p < 0.05, **p < 0.01, ***p < 0.001. 

WGCNA Weighted Gene Co-expression Network Analysis, GEO Gene Expression Omnibus, TCGA The Cancer Genome Atlas
patients with different survival states (Additional file 4: Fig. S4) and found that DLC1 expression was significantly lower in deceased patients (Additional file 4: Fig. S4A, $p = 0.0005$). Furthermore, Quantitative real-time PCR was used to detect DLC1 expression in bone marrow samples from 48 newly diagnosed AML patients in our center. The clinical characteristics of these patients are provided in Additional file 6: Table. S1. The Kaplan–Meier curve showed that patients with low DLC1 expression had a worse prognosis (Additional file 5: Fig. S5, $p = 0.028$).

DLC1 is a downregulated tumor suppressor gene and silenced by epigenetic mechanisms in human cancers, including several hematological malignancies [9–11]. Based on the bio-information database and external validation, our study suggests that DLC1 may be a potential marker affecting the prognosis of AML. Its deficiency at initial diagnosis is associated with a poor long-term prognosis. Future AML-matched methylation and RNA-seq are required to better elucidate the mechanism of DLC1 downregulation to guide the development of relevant molecular targeting drugs.

**Abbreviations**

AML: Acute myeloid leukemia; BP: Biological processes; CC: Cellular components; DEGs: Differentially expressed genes; GEO: Gene expression omnibus; GO: Gene ontology; KEGG: Kyoto encyclopedia of genes and genomes; LASSO: Least absolute shrinkage and selection operator; MF: Molecular functions; PCR: Polymerase chain reaction; SVM-RFE: Support vector machine recursive feature elimination; TCGA: The cancer genome atlas; WGCNA: Weighted gene co-expression network analysis.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s40164-022-00335-5.

**Additional file 1: Figure S1.** Correlation between gene significance and module membership in the gray module. A. The correlation between gene significance and module membership in the gray module. *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$.

**Additional file 2: Figure S2.** A Venn diagram shows the overlap of 22 optimal hub genes between GEO differential genes and WGCNA grey gene set.

**Additional file 3: Figure S3.** Identification of candidate hub genes to predict prognosis for AML patients. A. Partial likelihood deviance for different numbers of variables revealed by the LASSO regression model. Red dots represent the partial likelihood deviance values. Gray lines represent the partial likelihood deviance ± standard error. B. Fourteen candidate genes with minimum lambda values were obtained by LASSO regression with tenfold cross-validation. C. Candidate genes were filtrated from SVM-RFE algorithms. D. Five optimal hub genes overlapped between LASSO and SVM-RFE algorithm were shown by Venn diagram. Abbreviations: LASSO, least absolute shrinkage and selection operator; SVM-RFE, support vector machine recursive feature elimination.

**Additional file 4: Figure S4.** The expression levels of DLC1, NFB, DENND3B, TANC2, and ELAVL4 in AML patients with different survival status. Scatter plots of the five gene's expression level in AML patients with different survival status based on GEO dataset. *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$. Abbreviations: GEO, Gene Expression Omnibus.

**Acknowledgements**

We want to thank the patients and the physicians from the department of hematology, The First Affiliated Hospital of Soochow University.

**Author contributions**

XL and JQ designed and performed research studies and wrote the manuscript. XS and HW contributed to the study design and data analysis. XX and T pan analyzed the data. JY contributed to the collection and analysis of clinical data. YH contributed to the research design and manuscript revision and supervised the research. All authors read and approved the final manuscript.

**Funding**

This work was supported by the National Natural Science Foundation of China (81873432 and 82070143), grants from the Jiangsu Province of China (BE2021645), and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).

**Availability of data and materials**

Original data and code generated or used during the study are available from the corresponding author if necessary.

**Declarations**

**Ethics approval and consent to participate**

This research involving human samples was performed in accordance with the ethical standards of the institutional and national research committee and the 1964 Helsinki Declaration. This study was approved by the Research Ethical Review Committee of the First Affiliated Hospital of Soochow University.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that there is no conflict of interest.

**Author details**

1. National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou 215006, Jiangsu, People’s Republic of China. 2. Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. 3. Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China. 4. State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China.

**Received:** 2 June 2022   **Accepted:** 8 October 2022

**Published online:** 18 October 2022

**References**

1. Newell LF, Cook RJ. Advances in acute myeloid leukemia. BMJ. 2021;375:n2026.
2. Julisson G, Hagberg O, Lazarevic V, Ölander E, Antunovic P, Cammenga J, Wennström L, Möllgård L, Brune M, Jädersten M, et al. Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period. Blood. 2019;134(18):1558–61.
3. Allemani C, Matsuda T, Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J, et al. Global surveillance
of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–75.

4. Bullinger L, Döhner K, Döhner H. Genomics of acute myeloid leukemia diagnosis and pathways. J Clin Oncol. 2017;35(9):934–46.

5. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik V, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–21.

6. Niemira M, Collin F, Szalkowska A, Bielinska A, Chwialkowska K, Reszec J, Nikiński J, Kwasniewski M, Kretowski A. Molecular signature of subtypes of non-small-cell lung cancer by large-scale transcriptional profiling identification of key modules and genes by weighted gene co-expression network analysis (WGCNA). Cancers (Basel). 2019. https://doi.org/10.3390/cancers12010037.

7. Vasquez MM, Hu C, Roe DJ, Chen Z, Halonen M, Guerra S. Least absolute shrinkage and selection operator type methods for the identification of serum biomarkers of overweight and obesity: simulation and application. BMC Med Res Methodol. 2016;16(1):154.

8. Sanz H, Valim C, Vegas E, Oliver JM, Reverter F. SVM-RFE: selection and visualization of the most relevant features through non-linear kernels. BMC Bioinform. 2018;19(1):432.

9. Ulmannova-Benson V, Guan M, Zhou X, Tripathi V, Yang YY, Zimonjic DR, Pospescu NC. DLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathway. Leukemia. 2009;23(2):383–90.

10. Taylor KH, Pena-Hernandez KE, Davis JW, Arthur GL, Duff DJ, Shi H, Rahmatpanah FB, Sjahputera O, Caldwell CW. Large-scale CpG methylation analysis identifies novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia. Cancer Res. 2007;67(6):2617–25.

11. Sanchez-Solana B, Wang D, Qian X, Velayoudame P, Simanshu DK, Acharya JK, Lowy DR. The tumor suppressor activity of DLC1 requires the interaction of its START domain with Phosphatidylinerine, PLCD1, and Caveolin-1. Mol Cancer. 2021;20(1):141.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.